Humana
Healthy Horizons®
in Louisiana

Notification:	**HUM 9250**
Category:	**HCPCS - Drugs & Biologicals**
Topic:	**Louisiana Medicaid: bevacizumab and its biosimilars – HCPCS codes J9035, Q5107, Q5118, Q5126 and Q5129**
What is changing? / Change Description:	**For providers with a specialty other than home infusion therapy or pharmacy, we limit reimbursement of charges for HCPCS J9035, Q5107, Q5118, Q5126 or Q5129 to no more than 188 units per date of service for patients 15 years old or older if billed with any of the following diagnoses:** **• Astrocytoma** **• Glioblastoma multiforme** **• High-grade glioma** **• Intracranial and spinal ependymoma** **• Medulloblastoma** **• Oligodendroglioma** **• Pediatric diffuse high-grade glioma**
Why is Humana making this change? / Change Reason:	**The limitations listed above were established according to the FDA-approved package insert, prescribing information and pharmaceutical compendia.** **Note: The limitations described above are based on maximum dosages established in milligrams. If any units are denied, the provider may dispute the decision through the appropriate process. The provider may submit information, including medical notes showing the patient's body weight, that substantiates the medical necessity of the additional units.**
Language:	**English**
Impacted Products:	**Medicaid- Louisiana**